Euda Health Holdings Ltd. has announced the filing of a prospectus supplement as part of its At The Market Offering Agreement with Chardan Capital Markets LLC. Under this agreement, Euda Health may issue and sell up to $10 million of its ordinary shares. The prospectus supplement is part of the company's Registration Statement on Form F-3, which was filed with the Securities and Exchange Commission and became effective in November 2024. The company is not obligated to sell any shares, and the offering will conclude once all shares are sold or the agreement is terminated. Legal opinion regarding the offering has been provided by Conyers Dill & Pearman Pte. Ltd. This filing does not constitute an offer to sell or buy the shares in any jurisdiction where such actions would be unlawful.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.